CVRx’s Hypertension Implant Gains FDA Humanitarian Exemption
This article was originally published in The Gray Sheet
Executive Summary
The humanitarian device exemption for the Barostim neo legacy implantable electronic stimulator for hypertension is CVRx’ first commercial approval in the U.S. The Minneapolis company is also developing the Barostim therapy for treatment of heart failure